Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in
Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
What is the effect of immunotherapy drugs (nivolumab or brentuximab vedotin) when
given with combination chemotherapy in treating patients with newly diagnosed stage
III or IV classic Hodgkin lymphoma?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This randomized phase III trial compares immunotherapy drugs (nivolumab or brentuximab
vedotin) when given with combination chemotherapy in treating patients with newly
diagnosed stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal
antibodies, such as nivolumab, may help the body's immune system attack the cancer,
and may interfere with the ability of tumor cells to grow and spread. Brentuximab
vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin.
Brentuximab attaches to cancer cells in a targeted way and delivers vedotin to kill
them. Drugs used in chemotherapy, such as doxorubicin, vinblastine, and dacarbazine,
work in different ways to stop the growth of cancer cells, either by killing the cells,
by stopping them from dividing, or by stopping them from spreading. The addition of
nivolumab or brentuximab vedotin to combination chemotherapy may shrink the cancer
or extend the time without disease symptoms coming back.
Study Reference #: CLYM19112
Lead Researcher (Principal Investigator)
Jonathan Friedberg, MD
Study Contact InformationStudy Coordinator: Delaney Dretto
Phone: (585) 275-5825
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search